7LO9 image
Deposition Date 2021-02-09
Release Date 2021-12-22
Last Version Date 2024-05-22
Entry Detail
PDB ID:
7LO9
Keywords:
Title:
RNA dodecamer containing a GNA A residue
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
1.78 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 32
Macromolecular Entities
Polymer Type:polyribonucleotide
Molecule:Chains: A,B,C,D
Chain IDs:A, B, C, D
Chain Length:12
Number of Molecules:4
Biological Source:synthetic construct
Primary Citation
Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs.
Nucleic Acids Res. 49 10851 10867 (2021)
PMID: 34648028 DOI: 10.1093/nar/gkab916

Abstact

We recently reported that RNAi-mediated off-target effects are important drivers of the hepatotoxicity observed for a subset of GalNAc-siRNA conjugates in rodents, and that these findings could be mitigated by seed-pairing destabilization using a single GNA nucleotide placed within the seed region of the guide strand. Here, we report further investigation of the unique and poorly understood GNA/RNA cross-pairing behavior to better inform GNA-containing siRNA design. A reexamination of published GNA homoduplex crystal structures, along with a novel structure containing a single (S)-GNA-A residue in duplex RNA, indicated that GNA nucleotides universally adopt a rotated nucleobase orientation within all duplex contexts. Such an orientation strongly affects GNA-C and GNA-G but not GNA-A or GNA-T pairing in GNA/RNA heteroduplexes. Transposition of the hydrogen-bond donor/acceptor pairs using the novel (S)-GNA-isocytidine and -isoguanosine nucleotides could rescue productive base-pairing with the complementary G or C ribonucleotides, respectively. GalNAc-siRNAs containing these GNA isonucleotides showed an improved in vitro activity, a similar improvement in off-target profile, and maintained in vivo activity and guide strand liver levels more consistent with the parent siRNAs than those modified with isomeric GNA-C or -G, thereby expanding our toolbox for the design of siRNAs with minimized off-target activity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures